The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2009The Polo Like Kinases (PLK2 and PLK3) as Therapeutic Targets for Parkinson's Disease
Objective/Rationale:
Phosphorylation of alpha-synuclein at serine 129 is characteristic of Parkinson's disease (PD) and related alpha-synulceinopathies. Unraveling the role of phosphorylation in... -
Target Validation, 2009The Therapeutic Role of CMA-MEF2D in the Survival of DA Neurons
Objective/Rationale:
Parkinson’s Disease is caused by the death of a particular group of dopaminergic (DA) neurons in the brain. Our recent studies revealed that a nuclear protein named MEF2D is... -
Target Validation, 2009SHP-2 Phosphatase: A New Pharmacological Target for Parkinson's Disease?
Objective/Rationale:
Levodopa, the most effective therapy for Parkinson’s disease, induces severe involuntary movements termed dyskinesias. The development of these motor dysfunctions has been... -
Target Validation, 2009Validation of Nurr1 as a Drug Target for the Treatment of PD
Objective/Rationale:
Pharmacological methods to prevent or delay the degeneration of dopaminergic neurons in Parkinson’s disease (PD) are not available. We propose that Nurr1, a protein found in these... -
Target Validation, 2009Validation of Cyclophilin D, a Protein Involved in the Mitochondrial Permeability Transition, as a Target for Parkinson's Disease Therapy
Objective/Rationale:
Mitochondria dysfunction has long been proposed to contribute to the pathogenesis of Parkinson’s Disease. In addition to their role in ATP production, mitochondria play an... -
Therapeutics Development Initiative, 2009Dose-Response Assessment of ReS9-S7, a First-in-Class, Disease-modifying Drug Candidate for Treatment of Parkinson's Disease
Objective/Rationale:
ReS9-S7, a novel disease-modifying drug candidate directed against alpha-synuclein instigated neuronal toxicity, is planned to enter clinical Phase I studies in 2009/2010...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.